You are here

FDA to consider approval of new class of cholesterol drugs

PCSK9 inhibitors are self-injected every 2 weeks, and work by blocking substance that hinders liver's ability to remove cholesterol from blood

drugs150610.jpg
A federal advisory committee this week will decide whether to recommend approval of the first in a new class of drugs that many experts believe could significantly cut the risk of strokes and heart attacks, a leading cause of death for Americans.

Washington

A FEDERAL advisory committee this week will decide whether to recommend approval of the first in a new class of drugs that many experts believe could significantly cut the risk of strokes and heart attacks, a leading cause of death for Americans.

The highly anticipated

sentifi.com

Market voices on:

Powered by GET.comGetCom